All In Biotech

Drug Trial Radar · NCT04512963

Phase I Study of Progerinin in Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Aug 24, 2020

Primary completion

Jul 27, 2021

Study completion Jul 27, 2021

Sponsor

Sponsor type
Industry
Collaborators
Amarex Clinical Research
First posted
Aug 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

PRG-PRO-001 is a Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose (SAD) Study including a food interaction study, followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers. This is a first-in-human study. The study aims to determine the safety and tolerability of Progerinin after single and multiple doses in healthy volunteers and to evaluate the pharmacokinetics (PK) of Progerinin after single and multiple dose administrations in healthy volunteers.

Conditions

  • Hutchinson-Gilford Progeria Syndrome
  • Werner Syndrome

Interventions

  • ProgerininDrug

    100 mg/g nano-suspension for oral use

  • PlaceboDrug

    A substance that has no therapeutic effect, used as a control in testing Progerinin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: Day 1 through 7 days after the last study drug administration
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 through 7 days after the last study drug administration
  3. Incidence of withdrawals due to Adverse Events (AEs)Time frame: Day 1 through 7 days after the last study drug administration
  4. Incidence of abnormal blood work tests results, abnormal Urinalysis and positive Pregnancy testTime frame: At baseline, 72 to 96 hours after the last study drug administration, and on Day 7 after the first and the last study drug administration
  5. Change in vital signsTime frame: At pre-dose, over 96 hours after study drug administration, and on Day 7 after the last study drug administration
  6. Incidence of abnormal ECG parametersTime frame: At pre-dose, over 96 hours after study drug administration, and on Day 7 after the last study drug administration
  7. Incidence of abnormal physical examination findingsTime frame: At baseline, 96 hours after the last study drug administration, and on Day 7 after the last study drug administration
  8. Maximum observed plasma drug concentration (Cmax)Time frame: 0-96 hours
  9. Apparent terminal elimination half-life (t1/2)Time frame: 0-96 hours
  10. Time to maximum observed plasma drug concentration (Tmax)Time frame: 0-96 hours
  11. Area under the plasma drug concentration-time curve (AUC)Time frame: 0-96 hours
  12. Percentage of AUC0-∞ extrapolated from Tlast to infinity (AUCext)Time frame: 0-96 hours
  13. Apparent plasma clearance (CL/F)Time frame: 0-96 hours
  14. Apparent Volume of distribution (Vz/F)Time frame: 0-96 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRG S&T Investigational Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.